Jean‐Marc Navenot

3.1k total citations
25 papers, 370 citations indexed

About

Jean‐Marc Navenot is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Jean‐Marc Navenot has authored 25 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Immunology and 7 papers in Genetics. Recurrent topics in Jean‐Marc Navenot's work include CAR-T cell therapy research (11 papers), Immunotherapy and Immune Responses (7 papers) and Blood groups and transfusion (7 papers). Jean‐Marc Navenot is often cited by papers focused on CAR-T cell therapy research (11 papers), Immunotherapy and Immune Responses (7 papers) and Blood groups and transfusion (7 papers). Jean‐Marc Navenot collaborates with scholars based in United States, France and Switzerland. Jean‐Marc Navenot's co-authors include Dominique Blanchard, J. Y. Muller, D. Kay Blanchard, Daniel J. Bernard, Elliot Norry, Trupti Trivedi, Jean‐Pierre Louboutin, Marcello Villanova, J. L. Harousseau and Thomas Faitg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Jean‐Marc Navenot

25 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Marc Navenot United States 12 177 154 106 80 65 25 370
Alexis Talbot France 11 86 0.5× 180 1.2× 111 1.0× 191 2.4× 44 0.7× 46 409
Hiroshi Tomizuka Japan 12 221 1.2× 85 0.6× 80 0.8× 100 1.3× 12 0.2× 25 399
Sandra Grässle Germany 6 163 0.9× 43 0.3× 139 1.3× 100 1.3× 38 0.6× 7 375
Enrico Maffini Italy 12 128 0.7× 155 1.0× 204 1.9× 104 1.3× 29 0.4× 35 456
Alice M. Coughlan United Kingdom 9 202 1.1× 44 0.3× 21 0.2× 102 1.3× 40 0.6× 10 363
Hirotsugu Oda Japan 10 283 1.6× 40 0.3× 59 0.6× 312 3.9× 45 0.7× 16 498
Giovanni A. M. Povoleri United Kingdom 10 375 2.1× 58 0.4× 60 0.6× 92 1.1× 26 0.4× 11 493
Jörg Faber Germany 11 106 0.6× 192 1.2× 109 1.0× 144 1.8× 55 0.8× 31 466
Alessandro Crotta United States 7 55 0.3× 273 1.8× 99 0.9× 48 0.6× 43 0.7× 26 369
Christine Deppong United States 11 453 2.6× 69 0.4× 35 0.3× 46 0.6× 28 0.4× 14 529

Countries citing papers authored by Jean‐Marc Navenot

Since Specialization
Citations

This map shows the geographic impact of Jean‐Marc Navenot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Marc Navenot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Marc Navenot more than expected).

Fields of papers citing papers by Jean‐Marc Navenot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Marc Navenot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Marc Navenot. The network helps show where Jean‐Marc Navenot may publish in the future.

Co-authorship network of co-authors of Jean‐Marc Navenot

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Marc Navenot. A scholar is included among the top collaborators of Jean‐Marc Navenot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Marc Navenot. Jean‐Marc Navenot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aggen, David H., David S. Hong, Jeffrey Clarke, et al.. (2023). Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer.. Journal of Clinical Oncology. 41(6_suppl). 517–517. 1 indexed citations
2.
Murphy, Mariela A. Blum, Jaffer A. Ajani, Brian Andrew Van Tine, et al.. (2023). Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.. Journal of Clinical Oncology. 41(4_suppl). 349–349. 3 indexed citations
3.
Wang, Tianjiao, Jean‐Marc Navenot, Stavros Rafail, et al.. (2022). Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients. Cancer Research. 82(12_Supplement). LB001–LB001. 2 indexed citations
4.
Hong, David S., Marcus O. Butler, Russell K. Pachynski, et al.. (2020). 285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors. SHILAP Revista de lepidopterología. A174.2–A174. 1 indexed citations
5.
Blumenschein, George R., Siddhartha Devarakonda, Melissa L. Johnson, et al.. (2020). 278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer. SHILAP Revista de lepidopterología. A169.2–A170. 2 indexed citations
6.
Stadtmauer, Edward A., Thomas Faitg, Daniel E. Lowther, et al.. (2019). Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Advances. 3(13). 2022–2034. 69 indexed citations
7.
O’Rourke, Donald M., MacLean P. Nasrallah, Jennifer D. Morrissette, et al.. (2016). Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. Cancer Research. 76(14_Supplement). LB–83. 3 indexed citations
8.
Louboutin, Jean‐Pierre, Jean‐Marc Navenot, Karl Rouger, & Dominique Blanchard. (2003). S‐protein is expressed in necrotic fibers in Duchenne muscular dystrophy and polymyositis. Muscle & Nerve. 27(5). 575–581. 7 indexed citations
9.
Navenot, Jean‐Marc, J. Y. Muller, & D. Kay Blanchard. (1998). Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes. Transfusion. 38(4). 337–342. 29 indexed citations
10.
Louboutin, Jean‐Pierre, Jean‐Marc Navenot, Marcello Villanova, et al.. (1998). X-linked vacuolated myopathy: Membrane attack complex deposition on the surface membrane of injured muscle fibers is not accompanied by S-protein. Muscle & Nerve. 21(7). 932–935. 6 indexed citations
11.
Navenot, Jean‐Marc, Taha Merghoub, Rolande Ducrocq, et al.. (1998). New method for quantitative determination of fetal hemoglobin‐containing red blood cells by flow cytometry: Application to Sickle‐Cell Disease. Cytometry. 32(3). 186–190. 3 indexed citations
12.
Navenot, Jean‐Marc, Taha Merghoub, Rolande Ducrocq, et al.. (1998). New method for quantitative determination of fetal hemoglobin-containing red blood cells by flow cytometry: Application to Sickle-Cell Disease. Cytometry. 32(3). 186–190. 25 indexed citations
13.
Navenot, Jean‐Marc, et al.. (1997). Expression of blood group i antigen and fetal hemoglobin in paroxysmal nocturnal hemoglobinuria. Transfusion. 37(3). 291–297. 12 indexed citations
14.
Navenot, Jean‐Marc, et al.. (1997). Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Muscle & Nerve. 20(1). 92–96. 28 indexed citations
15.
Blanchard, Dominique, et al.. (1997). Flow cytometry and immunoblotting analysis of monoclonal antibodies directed to complement regulatory proteins. Transfusion Clinique et Biologique. 4(1). 131–134. 5 indexed citations
16.
Navenot, Jean‐Marc, Daniel J. Bernard, J. L. Harousseau, J. Y. Muller, & Dominique Blanchard. (1996). Expression of Glycosyl-Phosphatidylinositol-Linked Glycoproteins in Blood Cells from Paroxysmal Nocturnal Haemoglobinuria Patients a Flow Cytometry Study using CD55, CD58 and CD59 Monoclonal Antibodies. Leukemia & lymphoma. 21(1-2). 143–151. 32 indexed citations
17.
Borche, L, Karen Thibaudeau, Jean‐Marc Navenot, Jean‐Paul Soulillou, & Dominique Blanchard. (1994). Cytolytic effect of human anti‐Gal IgM and complement on porcine endothelial cells: A kinetic analysis. Xenotransplantation. 1(2). 125–131. 14 indexed citations
18.
19.
Charreau, Béatrice, Laurent Tesson, Brigitte Le Mauff, et al.. (1994). PROTECTION OF RAT ENDOTHELIAL CELLS FROM PRIMATE COMPLEMENT-MEDIATED LYSIS BY EXPRESSION OF HUMAN CD59 AND/OR DECAY-ACCELERATING FACTOR. Transplantation. 58(11). 1222–1229. 19 indexed citations
20.
Navenot, Jean‐Marc, et al.. (1993). Diagnostic rapide des hémoglobinuries nocturnes paroxystiques par agglutination en gel. PubMed. 36(2). 135–147. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexis Talbot Breakdown of academic impact, for papers by Hiroshi Tomizuka Breakdown of academic impact, for papers by Sandra Grässle Breakdown of academic impact, for papers by Enrico Maffini Breakdown of academic impact, for papers by Alice M. Coughlan Breakdown of academic impact, for papers by Hirotsugu Oda Breakdown of academic impact, for papers by Giovanni A. M. Povoleri Breakdown of academic impact, for papers by Jörg Faber Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by Christine Deppong
Rankless by CCL
2026